Z K Wszolek

List of Publications by Year
in descending order

317 papers	24,382 citations	13099 68 h-index	9345 143 g-index
328 all docs	328 docs citations	328 times ranked	22325 citing authors

#	Article	IF	Citations
1	Neuropathological Findings of <scp>CSF1R</scp>â€Related Leukoencephalopathy After Longâ€Term Immunosuppressive Therapy. Movement Disorders, 2022, 37, 439-440.	3.9	8
2	LRRK2 R1441C mutation causing Parkinsonâ€™s Disease in an Egyptian family. Neurologia I Neurochirurgia Polska, 2022, , .	1.2	1
3	Association of Essential Tremor With Novel Risk Loci. JAMA Neurology, 2022, 79, 185.	9.0	17
4	Neuropathology of <scp>McLeod</scp> Syndrome. Movement Disorders, 2022, 37, 644-646.	3.9	5
5	Plasma PolyQ-ATXN3 Levels Associate With Cerebellar Degeneration and Behavioral Abnormalities in a New AAV-Based SCA3 Mouse Model. Frontiers in Cell and Developmental Biology, 2022, 10, 863089.	3.7	5
6	Inhibition of colony stimulating factor-1 receptor (CSF-1R) as a potential therapeutic strategy for neurodegenerative diseases: opportunities and challenges. Cellular and Molecular Life Sciences, 2022, 79, 219.	5.4	64
7	Poly (ADP-Ribose) and Î±â€“synuclein extracellular vesicles in patients with Parkinson disease: A possible biomarker of disease severity. PLoS ONE, 2022, 17, e0264446.	2.5	6
8	Neuroimaging phenotypes of CSF1Râ€related leukoencephalopathy: Systematic review, metaâ€analysis, and imaging recommendations. Journal of Internal Medicine, 2022, 291, 269-282.	6.0	14
9	Comprehensive cross-sectional and longitudinal analyses of plasma neurofilament light across FTD spectrum disorders. Cell Reports Medicine, 2022, 3, 100607.	6.5	21
10	Tau and neurofilament lightâ€chain as fluid biomarkers in spinocerebellar ataxia type 3. European Journal of Neurology, 2022, 29, 2439-2452.	3.3	25
11	Editorâ€™s Thank You to Our Authors and Reviewers. Neurologia I Neurochirurgia Polska, 2022, 56, 115-117.	1.2	0
12	Comment on: <scp>Polyglutamineâ€Expanded</scp> Ataxinâ€3: A Target Engagement Marker for Spinocerebellar Ataxia Type 3 in Peripheral Blood. Movement Disorders, 2022, 37, 1120-1121.	3.9	0
13	Reply to â€œProphylactic Allogeneic Hematopoietic Stem Cell Therapy for <scp>CSF1R</scp>â€Related Leukoencephalopathyâ€• Movement Disorders, 2022, 37, 1109-1110.	3.9	1
14	Sensitivity of the Social Behavior Observer Checklist to Early Symptoms of Patients With Frontotemporal Dementia. Neurology, 2022, , 10.1212/WNL.0000000000200582.	1.1	0
15	L-Dopa response, choreic dyskinesia, and dystonia in Perry syndrome. Parkinsonism and Related Disorders, 2022, 100, 19-23.	2.2	5
16	Cathepsin B p.Gly284Val Variant in Parkinsonâ€™s Disease Pathogenesis. International Journal of Molecular Sciences, 2022, 23, 7086.	4.1	5
17	Sensitive ELISA-based detection method for the mitophagy marker p-S65-Ub in human cells, autopsy brain, and blood samples. Autophagy, 2021, 17, 2613-2628.	9.1	29
18	Frequency of spinocerebellar ataxia mutations in patients with multiple system atrophy. Clinical Autonomic Research, 2021, 31, 117-125.	2.5	10

#	Article	IF	Citations
19	Is Preâ€Symptomatic Immunosuppression Protective in <scp>CSF1R</scp>â€Related Leukoencephalopathy?. Movement Disorders, 2021, 36, 852-856.	3.9	19
20	Message from the Editors of the Polish Journal of Neurology and Neurosurgery to the Authors of our Invited Editorials and Invited Reviews, and to our Reviewers. Neurologia I Neurochirurgia Polska, 2021, 55, 1-4.	1.2	0
21	Fine-mapping of the non-coding variation driving the Caucasian LRRK2 GWAS signal in Parkinson's disease. Parkinsonism and Related Disorders, 2021, 83, 22-30.	2.2	7
22	Association of Mitochondrial DNA Genomic Variation With Risk of Pick Disease. Neurology, 2021, 96, e1755-e1760.	1.1	1
23	Latent trait modeling of tau neuropathology in progressive supranuclear palsy. Acta Neuropathologica, 2021, 141, 667-680.	7.7	5
24	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
25	The AD tau core spontaneously self-assembles and recruits full-length tau to filaments. Cell Reports, 2021, 34, 108843.	6.4	30
26	Investigating ELOVL7 coding variants in multiple system atrophy. Neuroscience Letters, 2021, 749, 135723.	2.1	2
27	Editors of the Polish Journal of Neurology and Neurosurgery announce the first issue featuring a Leading Topic. Neurologia I Neurochirurgia Polska, 2021, 55, 119-119.	1.2	0
28	Frequency of mutations in PRKN, PINK1, and DJ1 in Patients With Early-Onset Parkinson Disease from neighboring countries in Central Europe. Parkinsonism and Related Disorders, 2021, 86, 48-51.	2.2	5
29	Genomewide Association Studies of <scp>LRRK2</scp> Modifiers of Parkinson's Disease. Annals of Neurology, 2021, 90, 76-88.	5.3	30
30	Editorial Board meeting of the Polish Journal of Neurology and Neurosurgery â€" announcement of the gold open access for the journal. Neurologia I Neurochirurgia Polska, 2021, 55, 237-238.	1.2	0
31	Genetics of Parkinsonâ€™s disease in the Polish population. Neurologia I Neurochirurgia Polska, 2021, 55, 241-252.	1.2	11
32	Reply to: â€œInvestigation of Disease Modifying Mechanisms in <scp>CSF1Râ€Related</scp> Leukoencephalopathyâ€• Movement Disorders, 2021, 36, 1471-1471.	3.9	1
33	First Polish case of CSF1R-related leukoencephalopathy. Neurologia I Neurochirurgia Polska, 2021, 55, 239-240.	1.2	10
34	Serum neurofilament light protein correlates with unfavorable clinical outcomes in hospitalized patients with COVID-19. Science Translational Medicine, 2021, 13, .	12.4	67
35	Treatment of <scp>CSF1R</scp>â€Related Leukoencephalopathy: Breaking New Ground. Movement Disorders, 2021, 36, 2901-2909.	3.9	25
36	Urine levels of the polyglutamine ataxin-3 protein are elevated in patients with spinocerebellar ataxia type 3. Parkinsonism and Related Disorders, 2021, 89, 151-154.	2.2	9

#	Article	IF	Citations
37	Clinical, pathological and genetic characteristics of Perry diseaseâ€"new cases and literature review. European Journal of Neurology, 2021, 28, 4010-4021.	3.3	10
38	Clinical features of autopsy-confirmed multiple system atrophy in the Mayo Clinic Florida brain bank. Parkinsonism and Related Disorders, 2021, 89, 155-161.	2.2	12
39	Apolipoprotein E regulates lipid metabolism and Î±-synuclein pathology in human iPSC-derived cerebral organoids. Acta Neuropathologica, 2021, 142, 807-825.	7.7	25
40	Latest bibliometric factors for the Polish Journal of Neurology and Neurosurgery. Neurologia I Neurochirurgia Polska, 2021, 55, 329-330.	1.2	0
41	APOE3 -Jacksonville (V236E) variant reduces self-aggregation and risk of dementia. Science Translational Medicine, 2021, 13, eabc9375.	12.4	37
42	Screening of <scp>GBA</scp> Mutations in Nigerian Patients with Parkinson's Disease. Movement Disorders, 2021, 36, 2971-2973.	3.9	4
43	Neuropathology of progressive supranuclear palsy after treatment with tilavonemab. Lancet Neurology, The, 2021, 20, 786-787.	10.2	9
44	Effects of sex and APOE on Parkinsonâ€™s Disease-related cognitive decline. Neurologia I Neurochirurgia Polska, 2021, 55, 559-566.	1.2	6
45	Professor JarosÅ‚aw SÅ‚awek elected Secretary of the International Association of Parkinsonism and Related Disorders. Neurologia I Neurochirurgia Polska, 2021, 55, 415-415.	1.2	0
46	Capgras syndrome in dementia with Lewy bodies: a possible association of severe cortical Lewy body pathology. Neurologia I Neurochirurgia Polska, 2021, , .	1.2	2
47	Adult-Onset Leukoencephalopathy With Axonal Spheroids and Pigmented Glia: Review of Clinical Manifestations as Foundations for Therapeutic Development. Frontiers in Neurology, 2021, 12, 788168.	2.4	24
48	Age at symptom onset and death and disease duration in genetic frontotemporal dementia: an international retrospective cohort study. Lancet Neurology, The, 2020, 19, 145-156.	10.2	175
49	Comment on: â€œThe Geographic Diversity of Spinocerebellar Ataxias (SCAs) in the Americas: A Systematic Reviewâ€• Movement Disorders Clinical Practice, 2020, 7, 237-238.	1.5	1
50	Toward allele-specific targeting therapy and pharmacodynamic marker for spinocerebellar ataxia type 3. Science Translational Medicine, 2020, 12, .	12.4	32
51	Association of mitochondrial genomic background with risk of Multiple System Atrophy. Parkinsonism and Related Disorders, 2020, 81, 200-204.	2.2	4
52	Plasma neurofilament light predicts mortality in patients with stroke. Science Translational Medicine, 2020, 12, .	12.4	51
53	Microglial replacement therapy: a potential therapeutic strategy for incurable CSF1R-related leukoencephalopathy. Acta Neuropathologica Communications, 2020, 8, 217.	5.2	33
54	Association of MAPT subhaplotypes with clinical and demographic features in Parkinsonâ€™s disease. Annals of Clinical and Translational Neurology, 2020, 7, 1557-1563.	3.7	8

#	Article	IF	Citations
55	Cognitive and behavioral profile of Perry syndrome in two families. Parkinsonism and Related Disorders, 2020, 77, 114-120.	2.2	7
56	GBA variation and susceptibility to multiple system atrophy. Parkinsonism and Related Disorders, 2020, 77, 64-69.	2.2	12
57	APOE4 exacerbates synapse loss and neurodegeneration in Alzheimerâ€™s disease patient iPSC-derived cerebral organoids. Nature Communications, 2020, 11, 5540.	12.8	172
58	Letter to the editor, â€œMovement disorders rounds: A case of missing pathology in a patient with LRRK2 Parkinson's diseaseâ€• Parkinsonism and Related Disorders, 2020, 79, 130.	2.2	0
59	Association of ABI3 and PLCG2 missense variants with disease risk and neuropathology in Lewy body disease and progressive supranuclear palsy. Acta Neuropathologica Communications, 2020, 8, 172.	5.2	8
60	Screening non-MAPT genes of the Chr17q21 H1 haplotype in Parkinson's disease. Parkinsonism and Related Disorders, 2020, 78, 138-144.	2.2	12
61	Associations of mitochondrial genomic variation with corticobasal degeneration, progressive supranuclear palsy, and neuropathological tau measures. Acta Neuropathologica Communications, 2020, 8, 162.	5.2	9
62	MAPT subhaplotypes in corticobasal degeneration: assessing associations with disease risk, severity of tau pathology, and clinical features. Acta Neuropathologica Communications, 2020, 8, 218.	5.2	8
63	Rates of Brain Atrophy Across Disease Stages in Familial Frontotemporal Dementia Associated With MAPT, GRN, and C9orf72 Pathogenic Variants. JAMA Network Open, 2020, 3, e2022847.	5.9	19
64	Genetic characterization of Parkinson's disease patients in Ecuador and Colombia. Parkinsonism and Related Disorders, 2020, 75, 27-29.	2.2	6
65	Loss of homeostatic microglial phenotype in CSF1R-related Leukoencephalopathy. Acta Neuropathologica Communications, 2020, 8, 72.	5.2	42
66	Clinical and pathologic features of cognitive-predominant corticobasal degeneration. Neurology, 2020, 95, e35-e45.	1.1	9
67	Subtypes of dementia with Lewy bodies are associated with Î±-synuclein and tau distribution. Neurology, 2020, 95, e155-e165.	1.1	47
68	Crohnâ€™s and Parkinsonâ€™s Disease-Associated LRRK2 Mutations Alter Type II Interferon Responses in Human CD14+ Blood Monocytes Ex Vivo. Journal of NeuroImmune Pharmacology, 2020, 15, 794-800.	4.1	15
69	Prevalence of GBA p.K198E mutation in Colombian and Hispanic populations. Parkinsonism and Related Disorders, 2020, 73, 16-18.	2.2	5
70	Trajectory of lobar atrophy in asymptomatic and symptomatic GRN mutation carriers: a longitudinal MRI study. Neurobiology of Aging, 2020, 88, 42-50.	3.1	14
71	Early-Onset Parkinson Disease Screening in Patients From Nigeria. Frontiers in Neurology, 2020, 11, 594927.	2.4	5
72	What can Parkinsonâ€™s disease teach us about COVID-19?. Neurologia I Neurochirurgia Polska, 2020, 54, 204-206.	1.2	19

#	Article	IF	Citations
73	Spinocerebellar ataxia type 6 family with phenotypic overlap with Multiple System Atrophy. Neurologia I Neurochirurgia Polska, 2020, 54, 350-355.	1.2	6
74	A practical approach to adult-onset white matter diseases, with illustrative cases. Neurologia I Neurochirurgia Polska, 2020, 54, 312-322.	1.2	1
75	How to write a scientific paper? Lessons from a distinguished scientist and editor. European Journal of Translational and Clinical Medicine, 2020, 3, 74-78.	0.1	0
76	The editors of Neurologia i Neurochirurgia Polska (the Polish Journal of Neurology and) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 622 Td (Ne	1.2	0
77	Response to â€œDoes amantadine have a protective effect against COVID-19?â€• Neurologia I Neurochirurgia Polska, 2020, 54, 286-287.	1.2	2
78	Further Increase of Impact Factor and CiteScoreâ„¢ of the Polish Journal of Neurology and Neurosurgery (Neurologia i Neurochirurgia Polska). Neurologia I Neurochirurgia Polska, 2020, 54, 289-290.	1.2	0
79	Polish Journal of Neurology and Neurosurgery (Neurologia i Neurochirurgia Polska) â€" update on publication status. Neurologia I Neurochirurgia Polska, 2020, 54, 483-485.	1.2	0
80	Polish Journal of Neurology and Neurosurgery (Neurologia i Neurochirurgia Polska) â€" a publication of increasing national and international stature. Neurologia I Neurochirurgia Polska, 2020, 54, 1-2.	1.2	0
81	Bioethics and informatics in medical studies during coronavirus disease 2019. Polish Archives of Internal Medicine, 2020, 130, 719.	0.4	0
82	Perry syndrome: a case of atypical parkinsonism with confirmed DCTN1 mutation: a response. New Zealand Medical Journal, 2020, 133, 84-85.	0.5	2
83	Clinicopathologic subtype of Alzheimer's disease presenting as corticobasal syndrome. Alzheimer's and Dementia, 2019, 15, 1218-1228.	0.8	34
84	Rates of lobar atrophy in asymptomatic MAPT mutation carriers. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 338-346.	3.7	22
85	Neuropathologic basis of frontotemporal dementia in progressive supranuclear palsy. Movement Disorders, 2019, 34, 1655-1662.	3.9	14
86	Progressive supranuclear palsy is not associated with neurogenic orthostatic hypotension. Neurology, 2019, 93, e1339-e1347.	1.1	16
87	Miro1 Marks Parkinsonâ€™s Disease Subset and Miro1 Reducer Rescues Neuron Loss in Parkinsonâ€™s Models. Cell Metabolism, 2019, 30, 1131-1140.e7.	16.2	96
88	A nonsynonymous mutation in PLCG2 reduces the risk of Alzheimerâ€™s disease, dementia with Lewy bodies and frontotemporal dementia, and increases the likelihood of longevity. Acta Neuropathologica, 2019, 138, 237-250.	7.7	87
89	Brain MR Spectroscopy Changes Precede Frontotemporal Lobar Degeneration Phenoconversion in Mapt Mutation Carriers. Journal of Neuroimaging, 2019, 29, 624-629.	2.0	9
90	Association of MAPT Subhaplotypes With Risk of Progressive Supranuclear Palsy and Severity of Tau Pathology. JAMA Neurology, 2019, 76, 710.	9.0	39

#	Article	IF	Citations
91	A proteomic signature for dementia with Lewy bodies. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 270-276.	2.4	18
92	Genome-wide analyses as part of the international FTLD-TDP whole-genome sequencing consortium reveals novel disease risk factors and increases support for immune dysfunction in FTLD. Acta Neuropathologica, 2019, 137, 879-899.	7.7	90
93	A patient clinically diagnosed as multiple system atrophy harboring LRRK2 p.G2019S. Clinical Parkinsonism & Related Disorders, 2019, 1, 100-101.	0.9	2
94	No evidence for DNM3 as genetic modifier of age at onset in idiopathic Parkinson's disease. Neurobiology of Aging, 2019, 74, 236.e1-236.e5.	3.1	1
95	Frontal lobe ¹ H MR spectroscopy in asymptomatic and symptomatic MAPT mutation carriers. Neurology, 2019, 93, e758-e765.	1.1	18
96	Partial loss of function of colonyâ€stimulating factor 1 receptor in a patient with white matter abnormalities. European Journal of Neurology, 2018, 25, 875-881.	3.3	9
97	Anticipation in a family with primary familial brain calcification caused by an SLC20A2 variant. Neurologia I Neurochirurgia Polska, 2018, 52, 386-389.	1.2	5
98	PINK1 Phosphorylates MIC60/Mitofilin to Control Structural Plasticity of Mitochondrial Crista Junctions. Molecular Cell, 2018, 69, 744-756.e6.	9.7	88
99	Letter to the Readership of the Polish Journal of Neurology and Neurosurgery. Neurologia I Neurochirurgia Polska, 2018, 52, 123.	1.2	0
100	Daytime sleepiness in dementia with Lewy bodies is associated with neuronal depletion of the nucleus basalis of Meynert. Parkinsonism and Related Disorders, 2018, 50, 99-103.	2.2	22
101	Multiple system atrophy and apolipoprotein E. Movement Disorders, 2018, 33, 647-650.	3.9	15
102	Comparison of clinical features among Parkinson's disease subtypes: A large retrospective study in a single center. Journal of the Neurological Sciences, 2018, 386, 39-45.	0.6	42
103	Slowly progressive dementia caused by MAPT R406W mutations: longitudinal report on a new kindred and systematic review. Alzheimer's Research and Therapy, 2018, 10, 2.	6.2	25
104	Potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations: a genome-wide association study. Lancet Neurology, The, 2018, 17, 548-558.	10.2	97
105	Diaphragmatic Pacemaker for Perry Syndrome. Mayo Clinic Proceedings, 2018, 93, 263.	3.0	7
106	Diagnostic criteria for adultâ€onset leukoencephalopathy with axonal spheroids and pigmented glia due to <scp>CSF</scp>1R mutation. European Journal of Neurology, 2018, 25, 142-147.	3.3	59
107	Establishing diagnostic criteria for Perry syndrome. Journal of Neurology, Neurosurgery and Psychiatry, 2018, 89, 482-487.	1.9	40
108	The limbic and neocortical contribution of Î±â€synuclein, tau, and amyloid Î² to disease duration in dementia with Lewy bodies. Alzheimer's and Dementia, 2018, 14, 330-339.	0.8	69

#	Article	IF	Citations
109	Atypical parkinsonian syndromes: a general neurologist's perspective. European Journal of Neurology, 2018, 25, 41-58.	3.3	46
110	Parkinson-Associated SNCA Enhancer Variants Revealed by Open Chromatin in Mouse Dopamine Neurons. American Journal of Human Genetics, 2018, 103, 874-892.	6.2	30
111	Association study between multiple system atrophy and TREM2 p.R47H. Neurology: Genetics, 2018, 4, e257.	1.9	9
112	CSF1R -related leukoencephalopathy. Neurology, 2018, 91, 1092-1104.	1.1	126
113	APOE Îµ2 is associated with increased tau pathology in primary tauopathy. Nature Communications, 2018, 9, 4388.	12.8	100
114	ABI3 and PLCG2 missense variants as risk factors for neurodegenerative diseases in Caucasians and African Americans. Molecular Neurodegeneration, 2018, 13, 53.	10.8	75
115	TRIO gene segregation in a family with cerebellar ataxia. Neurologia I Neurochirurgia Polska, 2018, 52, 743-749.	1.2	5
116	The PINK1 p.I368N Mutation Affects Protein Stability and Kinase Activity with Its Structural Change. Juntendo Medical Journal, 2018, 64, 17-30.	0.1	0
117	Wholeâ€exome sequencing for variant discovery in blepharospasm. Molecular Genetics & Genomic Medicine, 2018, 6, 601-626.	1.2	20
118	Age- and disease-dependent increase of the mitophagy marker phospho-ubiquitin in normal aging and Lewy body disease. Autophagy, 2018, 14, 1404-1418.	9.1	87
119	Replication of progressive supranuclear palsy genome-wide association study identifies SLCO1A2 and DUSP10 as new susceptibility loci. Molecular Neurodegeneration, 2018, 13, 37.	10.8	54
120	APOE Îµ4 is associated with severity of Lewy body pathology independent of Alzheimer pathology. Neurology, 2018, 91, e1182-e1195.	1.1	122
121	Identification and functional characterization of novel mutations including frameshift mutation in exon 4 of CSF1R in patients with adult-onset leukoencephalopathy with axonal spheroids and pigmented glia. Journal of Neurology, 2018, 265, 2415-2424.	3.6	23
122	Diffuse Lewy body disease manifesting as corticobasal syndrome. Neurology, 2018, 91, e268-e279.	1.1	37
123	Occurrence of Crohn's disease with Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2017, 37, 116-117.	2.2	26
124	APOE Îµ4/Îµ4 diminishes neurotrophic function of human iPSC-derived astrocytes. Human Molecular Genetics, 2017, 26, 2690-2700.	2.9	162
125	The PINK1 p.I368N mutation affects protein stability and ubiquitin kinase activity. Molecular Neurodegeneration, 2017, 12, 32.	10.8	62
126	DCTN1-related neurodegeneration: Perry syndrome and beyond. Parkinsonism and Related Disorders, 2017, 41, 14-24.	2.2	62

#	Article	IF	Citations
127	Reply: Heterozygous PINK1 p.G411S in rapid eye movement sleep behaviour disorder. Brain, 2017, 140, e33-e33.	7.6	2
128	Distribution and characteristics of transactive response DNA binding protein 43 kDa pathology in progressive supranuclear palsy. Movement Disorders, 2017, 32, 246-255.	3.9	46
129	Spinocerebellar ataxia 15: A phenotypic review and expansion. Neurologia I Neurochirurgia Polska, 2017, 51, 86-91.	1.2	12
130	Cognitive impairment in progressive supranuclear palsy is associated with tau burden. Movement Disorders, 2017, 32, 1772-1779.	3.9	46
131	Progranulin-mediated deficiency of cathepsin D results in FTD and NCL-like phenotypes in neurons derived from FTD patients. Human Molecular Genetics, 2017, 26, 4861-4872.	2.9	100
132	Brain calcification in a CSF1R mutation carrier precedes white matter degeneration. Movement Disorders, 2017, 32, 1493-1495.	3.9	4
133	DCTN1 variation in pathologically-confirmed PSP and CBD tauopathy. Parkinsonism and Related Disorders, 2017, 44, 151-153.	2.2	3
134	Reduced orexin immunoreactivity in Perry syndrome and multiple system atrophy. Parkinsonism and Related Disorders, 2017, 42, 85-89.	2.2	9
135	TIA1 Mutations in Amyotrophic Lateral Sclerosis and Frontotemporal Dementia Promote Phase Separation and Alter Stress Granule Dynamics. Neuron, 2017, 95, 808-816.e9.	8.1	493
136	Perry Syndrome: A Distinctive Type of TDP-43 Proteinopathy. Journal of Neuropathology and Experimental Neurology, 2017, 76, 676-682.	1.7	50
137	Heterozygous PINK1 p.G411S increases risk of Parkinsonâ€™s disease via a dominant-negative mechanism. Brain, 2017, 140, 98-117.	7.6	116
138	Profile of cognitive impairment and underlying pathology in multiple system atrophy. Movement Disorders, 2017, 32, 405-413.	3.9	95
139	<scp>S</scp>tudy of LRRK2 variation in tauopathy: Progressive supranuclear palsy and corticobasal degeneration. Movement Disorders, 2017, 32, 115-123.	3.9	48
140	FTDPâ€17 with Pick bodyâ€like inclusions associated with a novel tau mutation, p.E372G. Brain Pathology, 2017, 27, 612-626.	4.1	11
141	Clinical and genetic characterization of adultâ€onset leukoencephalopathy with axonal spheroids and pigmented glia associated with <scp>CSF</scp>1R mutation. European Journal of Neurology, 2017, 24, 37-45.	3.3	114
142	Clinicopathologic heterogeneity in frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDPâ€17) due to microtubuleâ€associated protein tau (MAPT) p.P301L mutation, including a patient with globular glial tauopathy. Neuropathology and Applied Neurobiology, 2017, 43, 200-214.	3.2	49
143	Diagnostic Value of Brain Calcifications in Adult-Onset Leukoencephalopathy with Axonal Spheroids and Pigmented Glia. American Journal of Neuroradiology, 2017, 38, 77-83.	2.4	50
144	Novel radiology method for investigating middle ear myoclonus. Clinical Anatomy, 2016, 29, 811-812.	2.7	1

#	Article	IF	Citations
145	Cerebellar ataxia in progressive supranuclear palsy: An autopsy study of PSPâ€€. Movement Disorders, 2016, 31, 653-662.	3.9	60
146	MAPT haplotype diversity in multiple system atrophy. Parkinsonism and Related Disorders, 2016, 30, 40-45.	2.2	23
147	RAB39B gene mutations are not a common cause of Parkinson's disease or dementia with Lewy bodies. Neurobiology of Aging, 2016, 45, 107-108.	3.1	21
148	Tremor in progressive supranuclear palsy. Parkinsonism and Related Disorders, 2016, 27, 93-97.	2.2	17
149	Hypertrophic olivary degeneration: A clinico-radiologic study. Parkinsonism and Related Disorders, 2016, 28, 36-40.	2.2	46
150	Deep brain stimulation for levodopa-refractory benign tremulous parkinsonism. Neurologia I Neurochirurgia Polska, 2016, 50, 383-386.	1.2	1
151	Primary familial brain calcification in the â€˜IBGC2â€™ kindred: All linkage roads lead toSLC20A2. Movement Disorders, 2016, 31, 1901-1904.	3.9	16
152	TREM2 p.R47H substitution is not associated with dementia with Lewy bodies. Neurology: Genetics, 2016, 2, e85.	1.9	16
153	Association ofGBAMutations and the E326K Polymorphism With Motor and Cognitive Progression in Parkinson Disease. JAMA Neurology, 2016, 73, 1217.	9.0	185
154	Cancer in Parkinsonâ€™s disease. Parkinsonism and Related Disorders, 2016, 31, 28-33.	2.2	41
155	Cerebral peduncle angle: Unreliable in differentiating progressive supranuclear palsy from other neurodegenerative diseases. Parkinsonism and Related Disorders, 2016, 32, 31-35.	2.2	5
156	LRRK2 variation and dementia with Lewy bodies. Parkinsonism and Related Disorders, 2016, 31, 98-103.	2.2	30
157	Identification of genetic modifiers of age-at-onset for familial Parkinsonâ€™s disease. Human Molecular Genetics, 2016, 25, 3849-3862.	2.9	44
158	Genome-wide association study in essential tremor identifies three new loci. Brain, 2016, 139, 3163-3169.	7.6	78
159	Rare variants in MC1R/TUBB3 exon 1 are not associated with <scp>P</scp>arkinson's disease. Annals of Neurology, 2016, 79, 331-331.	5.3	10
160	MAPT haplotype H1G is associated with increased risk of dementia with Lewy bodies. Alzheimer's and Dementia, 2016, 12, 1297-1304.	0.8	32
161	Association of Parkinson disease age of onset with DRD2, DRD3 and GRIN2B polymorphisms. Parkinsonism and Related Disorders, 2016, 22, 102-105.	2.2	15
162	Autosomal dominant Parkinson's disease caused by SNCA duplications. Parkinsonism and Related Disorders, 2016, 22, S1-S6.	2.2	144

#	Article	IF	Citations
163	Assessment of Olfactory Function in MAPT-Associated Neurodegenerative Disease Reveals Odor-Identification Irreproducibility as a Non-Disease-Specific, General Characteristic of Olfactory Dysfunction. PLoS ONE, 2016, 11, e0165112.	2.5	10
164	Genetics of Parkinson's disease: a review of SNCA and LRRK2. WiadomoÅ›ci Lekarskie, 2016, 69, 328-32.	0.3	9
165	(Pathoâ€)physiological relevance of <scp>PINK</scp> 1â€dependent ubiquitin phosphorylation. EMBO Reports, 2015, 16, 1114-1130.	4.5	147
166	Frontotemporal dementia-associated N279K tau mutant disrupts subcellular vesicle trafficking and induces cellular stress in iPSC-derived neural stem cells. Molecular Neurodegeneration, 2015, 10, 46.	10.8	58
167	DNAJC13 p.Asn855Ser mutation screening in Parkinson's disease and pathologically confirmed Lewy body disease patients. European Journal of Neurology, 2015, 22, 1323-1325.	3.3	21
168	CHCHD2 and Parkinson's disease. Lancet Neurology, The, 2015, 14, 679.	10.2	16
169	Mitochondrial targeting sequence variants of the CHCHD2 gene are a risk for Lewy body disorders. Neurology, 2015, 85, 2016-2025.	1.1	51
170	Chronic traumatic encephalopathy pathology in a neurodegenerative disorders brain bank. Acta Neuropathologica, 2015, 130, 877-889.	7.7	235
171	Three sib-pairs of autopsy-confirmed progressive supranuclear palsy. Parkinsonism and Related Disorders, 2015, 21, 101-105.	2.2	42
172	PARK10 is a major locus for sporadic neuropathologically confirmed Parkinson disease. Neurology, 2015, 84, 972-980.	1.1	48
173	Clinical presentation of a patient with SLC20A2 and THAP1 deletions: Differential diagnosis of oromandibular dystonia. Parkinsonism and Related Disorders, 2015, 21, 329-331.	2.2	5
174	Whole-Exome Sequencing as a Diagnostic Tool in a Family With Episodic Ataxia Type 1. Mayo Clinic Proceedings, 2015, 90, 366-371.	3.0	13
175	Genome-wide association study of corticobasal degeneration identifies risk variants shared with progressive supranuclear palsy. Nature Communications, 2015, 6, 7247.	12.8	170
176	When DLB, PD, and PSP masquerade as MSA. Neurology, 2015, 85, 404-412.	1.1	272
177	TREM2 R47H variant and risk of essential tremor: A cross-sectional international multicenter study. Parkinsonism and Related Disorders, 2015, 21, 306-309.	2.2	28
178	Role for the microtubule-associated protein tau variant p.A152T in risk of Î±-synucleinopathies. Neurology, 2015, 85, 1680-1686.	1.1	31
179	VPS35 and DNAJC13 disease-causing variants in essential tremor. European Journal of Human Genetics, 2015, 23, 887-888.	2.8	25
180	Exonic Re-Sequencing of the Chromosome 2q24.3 Parkinsonâ€™s Disease Locus. PLoS ONE, 2015, 10, e0128586.	2.5	0

#	Article	IF	Citations
181	Analysis of Nuclear Export Sequence Regions of FUS-Related RNA-Binding Proteins in Essential Tremor. PLoS ONE, 2014, 9, e111989.	2.5	10
182	LRRK2 exonic variants and risk of multiple system atrophy. Neurology, 2014, 83, 2256-2261.	1.1	46
183	A rare sequence variant in intron 1 of <scp>THAP</scp>1 is associated with primary dystonia. Molecular Genetics & Genomic Medicine, 2014, 2, 261-272.	1.2	24
184	In vivo dopaminergic and serotonergic dysfunction in DCTN1 gene mutation carriers. Movement Disorders, 2014, 29, 1197-1201.	3.9	15
185	Hereditary diffuse leukoencephalopathy with axonal spheroids. Neurology, 2014, 82, 102-103.	1.1	12
186	DCTN1Mutations and Progressive Supranuclear Palsyâ€“Like Phenotype. JAMA Neurology, 2014, 71, 655.	9.0	3
187	Thiol peroxidases ameliorate LRRK2 mutant-induced mitochondrial and dopaminergic neuronal degeneration in Drosophila. Human Molecular Genetics, 2014, 23, 3157-3165.	2.9	42
188	Agraphia in patients with frontotemporal dementia and parkinsonism linked to chromosome 17 with P301LMAPTmutation: dysexecutive, aphasic, apraxic or spatial phenomenon?. Neurocase, 2014, 20, 69-86.	0.6	14
189	SLC1A2 rs3794087 does not associate with essential tremor. Neurobiology of Aging, 2014, 35, 935.e9-935.e10.	3.1	15
190	Investigating FUS variation in Parkinson's disease. Parkinsonism and Related Disorders, 2014, 20, S147-S149.	2.2	9
191	Novel mutation in MAPT exon 13 (p.N410H) causes corticobasal degeneration. Acta Neuropathologica, 2014, 127, 271-282.	7.7	66
192	Latin Americaâ€™s first case of Perry syndrome and a new treatment option for respiratory insufficiency. Journal of Neurology, 2014, 261, 620-621.	3.6	14
193	Ribosomal Protein s15 Phosphorylation Mediates LRRK2 Neurodegeneration in Parkinsonâ€™s Disease. Cell, 2014, 157, 472-485.	28.9	239
194	SLC20A2 and THAP1 deletion in familial basal ganglia calcification with dystonia. Neurogenetics, 2014, 15, 23-30.	1.4	56
195	Genetic Screening and Functional Characterization ofPDGFRBMutations Associated with Basal Ganglia Calcification of Unknown Etiology. Human Mutation, 2014, 35, 964-971.	2.5	45
196	Ataxin-2 as potential disease modifier in C9ORF72 expansion carriers. Neurobiology of Aging, 2014, 35, 2421.e13-2421.e17.	3.1	74
197	Update on novel familial forms of Parkinson's disease and multiple system atrophy. Parkinsonism and Related Disorders, 2014, 20, S29-S34.	2.2	84
198	Early-onset Parkinson's disease due to PINK1 p.Q456X mutation â€“ Clinical and functional study. Parkinsonism and Related Disorders, 2014, 20, 1274-1278.	2.2	41

#	Article	IF	Citations
199	A familial form of parkinsonism, dementia, and motor neuron disease: A longitudinal study. Parkinsonism and Related Disorders, 2014, 20, 1129-1134.	2.2	6
200	Parkinsonian syndrome in familial frontotemporal dementia. Parkinsonism and Related Disorders, 2014, 20, 957-964.	2.2	140
201	Three families with Perry syndrome from distinct parts of the world. Parkinsonism and Related Disorders, 2014, 20, 884-888.	2.2	24
202	Genetic variation of the retromer subunits VPS26A/B-VPS29 in Parkinson's disease. Neurobiology of Aging, 2014, 35, 1958.e1-1958.e2.	3.1	19
203	ApoE variant p.V236E is associated with markedly reduced risk of Alzheimerâ€™s disease. Molecular Neurodegeneration, 2014, 9, 11.	10.8	57
204	Autosomal dominant cerebellar ataxia type III: a review of the phenotypic and genotypic characteristics. Orphanet Journal of Rare Diseases, 2013, 8, 14.	2.7	27
205	Novel A18T and pA29S substitutions in Î±-synuclein may be associated with sporadic Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 1057-1060.	2.2	63
206	Analysis of the C9orf72 repeat in Parkinson's disease, essential tremor and restless legs syndrome. Parkinsonism and Related Disorders, 2013, 19, 198-201.	2.2	37
207	Parkinsonian features in hereditary diffuse leukoencephalopathy with spheroids (HDLS) and CSF1R mutations. Parkinsonism and Related Disorders, 2013, 19, 869-877.	2.2	119
208	TARDBP mutations in Parkinson's disease. Parkinsonism and Related Disorders, 2013, 19, 312-315.	2.2	49
209	An adult-onset leukoencephalopathy with axonal spheroids and pigmented glia accompanied by brain calcifications. Journal of Neurology, 2013, 260, 2665-2668.	3.6	22
210	Similarities between familial and sporadic autopsy-proven progressive supranuclear palsy. Neurology, 2013, 80, 2076-2078.	1.1	31
211	CSF1R mutations link POLD and HDLS as a single disease entity. Neurology, 2013, 80, 1033-1040.	1.1	136
212	Diversity of pathological features other than Lewy bodies in familial Parkinson's disease due to SNCA mutations. American Journal of Neurodegenerative Disease, 2013, 2, 266-75.	0.1	19
213	Atypical Motor and Behavioral Presentations of Alzheimer Disease. Neurologist, 2012, 18, 266-272.	0.7	37
214	Characterization of frontotemporal dementia and/or amyotrophic lateral sclerosis associated with the GGGGCC repeat expansion in C9ORF72. Brain, 2012, 135, 765-783.	7.6	322
215	Mutations in the colony stimulating factor 1 receptor (CSF1R) gene cause hereditary diffuse leukoencephalopathy with spheroids. Nature Genetics, 2012, 44, 200-205.	21.4	428
216	Update on Genetics of Parkinsonism. Neurodegenerative Diseases, 2012, 10, 257-260.	1.4	23

#	Article	IF	Citations
217	Autosomal dominant Parkinson's disease. Parkinsonism and Related Disorders, 2012, 18, S7-S10.	2.2	39
218	A novel de novo pathogenic mutation in theCACNA1Agene. Movement Disorders, 2012, 27, 1578-1579.	3.9	3
219	Hereditary diffuse leukoencephalopathy with axonal spheroids (HDLS): A misdiagnosed disease entity. Journal of the Neurological Sciences, 2012, 314, 130-137.	0.6	73
220	MRI characteristics and scoring in HDLS due to CSF1R gene mutations. Neurology, 2012, 79, 566-574.	1.1	153
221	Pharmacological Rescue of Mitochondrial Deficits in iPSC-Derived Neural Cells from Patients with Familial Parkinsonâ€™s Disease. Science Translational Medicine, 2012, 4, 141ra90.	12.4	444
222	Identification of common variants influencing risk of the tauopathy progressive supranuclear palsy. Nature Genetics, 2011, 43, 699-705.	21.4	502
223	Ataxin-2 repeat-length variation and neurodegeneration. Human Molecular Genetics, 2011, 20, 3207-3212.	2.9	147
224	Expanded GGGGCC Hexanucleotide Repeat in Noncoding Region of C9ORF72 Causes Chromosome 9p-Linked FTD and ALS. Neuron, 2011, 72, 245-256.	8.1	4,176
225	Clinical and neuropathologic heterogeneity of c9FTD/ALS associated with hexanucleotide repeat expansion in C9ORF72. Acta Neuropathologica, 2011, 122, 673-690.	7.7	277
226	Clinical Aspects of Familial Forms of Frontotemporal Dementia Associated with Parkinsonism. Journal of Molecular Neuroscience, 2011, 45, 359-365.	2.3	17
227	Autosomal dominant cerebellar ataxia type I: A review of the phenotypic and genotypic characteristics. Orphanet Journal of Rare Diseases, 2011, 6, 33.	2.7	68
228	Anatomy of disturbed sleep in pallidoâ€pontoâ€nigral degeneration. Annals of Neurology, 2011, 69, 1014-1025.	5.3	10
229	MAPT H1 haplotype is a risk factor for essential tremor and multiple system atrophy. Neurology, 2011, 76, 670-672.	1.1	68
230	Diagnosis and Treatment of Common Forms of Tremor. Seminars in Neurology, 2011, 31, 065-077.	1.4	111
231	A family with parkinsonism, essential tremor, restless legs syndrome, and depression. Neurology, 2011, 76, 1623-1630.	1.1	29
232	LINGO1 and LINGO2 variants are associated with essential tremor and Parkinson disease. Neurogenetics, 2010, 11, 401-408.	1.4	114
233	Clinical implications of gene discovery in Parkinson's disease and parkinsonism. Movement Disorders, 2010, 25, S15-20.	3.9	17
234	Leucine-Rich Repeat Kinase 2 Gene-Associated Disease: Redefining Genotype-Phenotype Correlation. Neurodegenerative Diseases, 2010, 7, 175-179.	1.4	127

#	Article	IF	Citations
235	Frontotemporal Dementia. Blue Books of Neurology, 2010, 34, 397-416.	0.1	0
236	Elucidating the genetics and pathology of Perry syndrome. Journal of the Neurological Sciences, 2010, 289, 149-154.	0.6	112
237	In vivo detection of neuropathologic changes in presymptomatic MAPT mutation carriers: A PET and MRI study. Parkinsonism and Related Disorders, 2010, 16, 404-408.	2.2	67
238	Genetics of Parkinson disease and essential tremor. Current Opinion in Neurology, 2010, 23, 388-393.	3.6	31
239	Characterization of DCTN1 genetic variability in neurodegeneration. Neurology, 2009, 72, 2024-2028.	1.1	59
240	Leukoencephalopathy with spheroids (HDLS) and pigmentary leukodystrophy (POLD). Neurology, 2009, 72, 1953-1959.	1.1	98
241	Corticobasal syndrome with Alzheimer's disease pathology. Movement Disorders, 2009, 24, 152-153.	3.9	16
242	Brainstem atrophy on routine MR study in pallidopontonigral degeneration. Journal of Neurology, 2009, 256, 827-829.	3.6	5
243	Familial idiopathic basal ganglia calcification: a challenging clinicalâ€“pathological correlation. Journal of Neurology, 2009, 256, 839-842.	3.6	38
244	DCTN1 mutations in Perry syndrome. Nature Genetics, 2009, 41, 163-165.	21.4	285
245	Tauopathies with parkinsonism: clinical spectrum, neuropathologic basis, biological markers, and treatment options. European Journal of Neurology, 2009, 16, 297-309.	3.3	170
246	Pallidonigral TDP-43 pathology in Perry syndrome. Parkinsonism and Related Disorders, 2009, 15, 281-286.	2.2	89
247	Familial parkinsonism: Study of original Sagamihara PARK8 (I2020T) kindred with variable clinicopathologic outcomes. Parkinsonism and Related Disorders, 2009, 15, 300-306.	2.2	98
248	Clinical features of LRRK2 parkinsonism. Parkinsonism and Related Disorders, 2009, 15, S205-S208.	2.2	66
249	Clinical and Genetic Description of a Family With a High Prevalence of Autosomal Dominant Restless Legs Syndrome. Mayo Clinic Proceedings, 2009, 84, 134-138.	3.0	24
250	Clinical and genetic description of a family with a high prevalence of autosomal dominant restless legs syndrome. Mayo Clinic Proceedings, 2009, 84, 134-8.	3.0	7
251	Neurodegeneration involving putative respiratory neurons in Perry syndrome. Acta Neuropathologica, 2008, 115, 263-268.	7.7	56
252	Clinical, neuropathological and genotypic variability in SNCA A53T familial Parkinsonâ€™s disease. Acta Neuropathologica, 2008, 116, 25-35.	7.7	91

#	Article	IF	Citations
253	MR imaging of brainstem atrophy in progressive supranuclear palsy. Journal of Neurology, 2008, 255, 37-44.	3.6	46
254	Rapidly progressive familial parkinsonism with central hypoventilation, depression and weight loss (Perry syndrome)â€"A literature review. Parkinsonism and Related Disorders, 2008, 14, 1-7.	2.2	56
255	Insights into the dynamics of hereditary diffuse leukoencephalopathy with axonal spheroids. Neurology, 2008, 71, 925-929.	1.1	54
256	ARE PARKINSON DISEASE PATIENTS PROTECTED FROM SOME BUT NOT ALL CANCERS?. Neurology, 2008, 71, 1650-1651.	1.1	14
257	Progression of dopaminergic dysfunction in a LRRK2 kindred. Neurology, 2008, 71, 1790-1795.	1.1	112
258	Clinical-pathologic study of biomarkers in FTDP-17 (PPND family with N279K tau mutation). Parkinsonism and Related Disorders, 2007, 13, 230-239.	2.2	47
259	The Genetics of Frontotemporal Dementia. Neurologic Clinics, 2007, 25, 697-715.	1.8	13
260	Prevalence and clinical characteristics of restless legs syndrome in Japanese patients with Parkinson's disease. Movement Disorders, 2007, 22, 284-284.	3.9	2
261	ELAVL4, PARK10, and the Celts. Movement Disorders, 2007, 22, 585-587.	3.9	24
262	Frontotemporal dementia and parkinsonism linked to chromosome 17 with the N279K tau mutation. Neuropathology, 2007, 27, 73-80.	1.2	18
263	Lrrk2 and chronic inflammation are linked to pallido-ponto-nigral degeneration caused by the N279K tau mutation. Acta Neuropathologica, 2007, 114, 243-254.	7.7	20
264	Frontotemporal dementia and parkinsonism linked to chromosome 17 (FTDP-17). Orphanet Journal of Rare Diseases, 2006, 1, 30.	2.7	99
265	Absence of Rapid Eye Movement Sleep Behavior Disorder in 11 Members of the Pallidopontonigral Degeneration Kindred. Archives of Neurology, 2006, 63, 268.	4.5	27
266	Comprehensive analysis of the LRRK2 gene in sixty families with Parkinson's disease. European Journal of Human Genetics, 2006, 14, 322-331.	2.8	152
267	Hereditary diffuse leukoencephalopathy with spheroids: clinical, pathologic and genetic studies of a new kindred. Acta Neuropathologica, 2006, 111, 300-311.	7.7	84
268	PARK8 LRRK2 parkinsonism. Current Neurology and Neuroscience Reports, 2006, 6, 287-294.	4.2	19
269	Lrrk2 and Lewy body disease. Annals of Neurology, 2006, 59, 388-393.	5.3	259
270	Clinical Features of Parkinson Disease Patients With Homozygous Leucine-Rich Repeat Kinase 2 G2019S Mutations. Archives of Neurology, 2006, 63, 1250.	4.5	91

#	Article	IF	Citations
271	New and reliable MRI diagnosis for progressive supranuclear palsy. Neurology, 2006, 66, 781-781.	1.1	2
272	Brain acetylcholinesterase activity in FTDP-17 studied by PET. Neurology, 2006, 66, 1276-1277.	1.1	16
273	Autosomal dominant dystonia-plus with cerebral calcifications. Neurology, 2006, 67, 620-625.	1.1	40
274	PET in LRRK2 mutations: comparison to sporadic Parkinson's disease and evidence for presymptomatic compensation. Brain, 2005, 128, 2777-2785.	7.6	242
275	Severe vascular disturbance in a case of familial brain calcinosis. Acta Neuropathologica, 2005, 109, 643-653.	7.7	64
276	Lrrk2 pathogenic substitutions in Parkinson's disease. Neurogenetics, 2005, 6, 171-177.	1.4	237
277	Identification of a Novel LRRK2 Mutation Linked to Autosomal Dominant Parkinsonism: Evidence of a Common Founder across European Populations. American Journal of Human Genetics, 2005, 76, 672-680.	6.2	524
278	Heredofamilial Brain Calcinosis Syndrome. Mayo Clinic Proceedings, 2005, 80, 641-651.	3.0	73
279	The Effect of tau genotype on clinical features in FTDP-17. Parkinsonism and Related Disorders, 2005, 11, 205-208.	2.2	31
280	Mutations in LRRK2 Cause Autosomal-Dominant Parkinsonism with Pleomorphic Pathology. Neuron, 2004, 44, 601-607.	8.1	2,653
281	Autosomal dominant parkinsonism associated with variable synuclein and tau pathology. Neurology, 2004, 62, 1619-1622.	1.1	251
282	Genetic heterogeneity in familial idiopathic basal ganglia calcification (Fahr disease). Neurology, 2004, 63, 2165-2167.	1.1	119
283	Atrophy of superior cerebellar peduncle in progressive supranuclear palsy. Neurology, 2003, 60, 1766-1769.	1.1	120
284	Early and pre-symptomatic neuropsychological dysfunction in the PPND family with the N279K tau mutation. Parkinsonism and Related Disorders, 2003, 9, 265-270.	2.2	30
285	Hereditary tauopathies and parkinsonism. Advances in Neurology, 2003, 91, 153-63.	0.8	21
286	Clinical and genetic studies of families with the tau N279K mutation (FTDP-17). Neurology, 2002, 59, 1791-1793.	1.1	47
287	SCA-2 presenting as parkinsonism in an Alberta family. Neurology, 2002, 59, 1625-1627.	1.1	113
288	Magnetic Resonance Imaging and Deep Brain Stimulation. Neurosurgery, 2002, 51, 1423-1431.	1.1	34

#	Article	IF	Citations
289	Physiologic assessment of autonomic dysfunction in pallidopontonigral degeneration with N279K mutation in the tau gene on chromosome 17. Autonomic Neuroscience: Basic and Clinical, 2002, 102, 71-77.	2.8	16
290	Japanese family with parkinsonism, depression, weight loss, and central hypoventilation. Neurology, 2002, 58, 1025-1030.	1.1	32
291	Clinical Features and Disease Haplotypes of Individuals With the N279K tau Gene Mutation. Archives of Neurology, 2002, 59, 943.	4.5	39
292	Neuropathology of two members of a German-American kindred (Family C) with late onset parkinsonism. Acta Neuropathologica, 2002, 103, 344-350.	7.7	17
293	Phenotypic correlations in FTDP-17. Neurobiology of Aging, 2001, 22, 89-107.	3.1	229
294	Positron emission tomography in pallido-ponto-nigral degeneration (PPND) family (frontotemporal) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 and Related Disorders, 2001, 7, 81-88.	2.2	27
295	Interest in genetic testing in pallido-ponto-nigral degeneration (PPND): a family with frontotemporal dementia with Parkinsonism linked to chromosome 17. European Journal of Neurology, 2001, 8, 179-183.	3.3	11
296	Frontotemporal dementia and Parkinsonism linked to chromosome 17 (FTDP-17): PPND family. A longitudinal videotape demonstration. Movement Disorders, 2001, 16, 756-760.	3.9	8
297	Familial Parkinson's disease and related conditions. Clinical genetics. Advances in Neurology, 2001, 86, 33-43.	0.8	5
298	Predominance of brain tumors in an extended Li-Fraumeni (SBLA) kindred, including a case of Sturge-Weber syndrome. , 2000, 88, 433-439.		21
299	Reduced expression of the G209A ?-synuclein allele in familial parkinsonism. Annals of Neurology, 1999, 46, 374-381.	5.3	89
300	Molecular genetics of familial parkinsonism. Parkinsonism and Related Disorders, 1999, 5, 145-155.	2.2	8
301	Rare and unusual parkinsonian syndromes. Advances in Neurology, 1999, 80, 369-76.	0.8	0
302	A susceptibility locus for Parkinson's disease maps to chromosome 2p13. Nature Genetics, 1998, 18, 262-265.	21.4	486
303	Clinical neurophysiologic findings in patients with rapidly progressive familial parkinsonism and dementia with pallido-ponto-nigral degeneration. Electroencephalography and Clinical Neurophysiology, 1998, 107, 213-222.	0.3	24
304	The Neuropathology of a Chromosome 17-Linked Autosomal Dominant Parkinsonism and Dementia (â€œPallido-Ponto-Nigral Degenerationâ€). Journal of Neuropathology and Experimental Neurology, 1998, 57, 588-601.	1.7	133
305	Olfactory dysfunction in Parkinson's disease. Clinical Neuroscience, 1998, 5, 94-101.	0.1	5
306	Seizures after orthotopic liver transplantation. Seizure: the Journal of the British Epilepsy Association, 1997, 6, 31-39.	2.0	40

#	Article	IF	Citations
307	Rapidly progressive autosomal dominant Parkinsonism and dementia with Pallido-Ponto-Nigral Gegeneration (PPND) and Disinhibition-Dementia-Parkinsonism-Amyotrophy Complex (DDPAC) are clinically distinct conditions that are both linked to 17q21-22. Parkinsonism and Related Disorders, 1997, 3, 67-76.	2.2	14
308	German-Canadian family (family A) with parkinsonism, amyotrophy, and dementia â€" Longitudinal observations. Parkinsonism and Related Disorders, 1997, 3, 125-139.	2.2	67
309	Complex partial status epilepticus after bone marrow transplantation for non-Hodgkinâ€™s lymphoma. Bone Marrow Transplantation, 1997, 19, 637-638.	2.4	6
310	Familial parkinsonism, dementia, and lewy body disease: Study of family G. Annals of Neurology, 1997, 42, 638-643.	5.3	47
311	Letters to the editor. Muscle and Nerve, 1996, 19, 109-114.	2.2	0
312	Anorectal function in fluctuating (onâ€off) Parkinson's disease: Evaluation by combined anorectal manometry and electromyography. Movement Disorders, 1995, 10, 650-657.	3.9	72
313	Western Nebraska Family (Family D) with Autosomal Dominant Parkinsonism. Neurology, 1995, 45, 502-505.	1.1	116
314	Familial parkinsonism: Our experience and review. Parkinsonism and Related Disorders, 1995, 1, 35-46.	2.2	51
315	Rapidly progressive autosomal dominant parkinsonism and dementia with pallido-ponto-nigral degeneration. Annals of Neurology, 1992, 32, 312-320.	5.3	221
316	Genetic considerations in movement disorders. Current Opinion in Neurology and Neurosurgery, 1992, 5, 324-30.	0.4	2
317	Epileptiform electroencephalographic abnormalities in liver transplant recipients. Annals of Neurology, 1991, 30, 37-41.	5.3	34